Levetiracetam Tablet, Film Coated
Product Images NDC 63629-4137

10 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 63629-4137). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Fdc77d21 Ac52 4c9e B53f 43681e769687 01)

Figure 1 (Fdc77d21 Ac52 4c9e B53f 43681e769687 01)
A formula for calculating total daily dose (mL/day) based on daily dose in mg/kg/day multiplied by patient weight in kg, divided by 100 mg/mL concentration. This text likely appears in prescription dose-related information.*
FDA Label Image

Figure 2 (Fdc77d21 Ac52 4c9e B53f 43681e769687 02)

Figure 2 (Fdc77d21 Ac52 4c9e B53f 43681e769687 02)
This image shows a formula used to calculate creatinine clearance (CLcr) involving age, weight, serum creatinine, and body surface area (BSA). It includes an adjustment factor for female patients and the method to adjust CLcr for BSA in milliliters per minute.*
FDA Label Image

Structure (Fdc77d21 Ac52 4c9e B53f 43681e769687 03)

Structure (Fdc77d21 Ac52 4c9e B53f 43681e769687 03)
Chemical structure of levetiracetam showing its molecular arrangement including a pyrrolidone ring and functional groups relevant to the active ingredient levetiracetam.*
FDA Label Image

Figure 4 (Fdc77d21 Ac52 4c9e B53f 43681e769687 04)

Figure 4 (Fdc77d21 Ac52 4c9e B53f 43681e769687 04)
A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The vertical axis represents the percentage of patients (0% to 45%). The Placebo group shows 7.4%, Levetiracetam 1000 mg/day shows 37.1%, and Levetiracetam 3000 mg/day shows 39.6%. Patient counts for each group are indicated below the bars.*
FDA Label Image

Figure 5 (Fdc77d21 Ac52 4c9e B53f 43681e769687 05)

Figure 5 (Fdc77d21 Ac52 4c9e B53f 43681e769687 05)
A bar graph showing the percentage of patients in three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The y-axis represents the percentage of patients, and the x-axis lists the treatment groups with sample sizes (N).*
FDA Label Image

Figure 6 (Fdc77d21 Ac52 4c9e B53f 43681e769687 06)

Figure 6 (Fdc77d21 Ac52 4c9e B53f 43681e769687 06)
A bar chart comparing the percentage of patients between two groups: Placebo and Levetiracetam 3000 mg/day (divided dose). The y-axis represents the percentage of patients, with the placebo group showing 14.4% and the Levetiracetam group showing 39.4%. Sample sizes are 104 for placebo and 180 for Levetiracetam.*
FDA Label Image

Figure 7 (Fdc77d21 Ac52 4c9e B53f 43681e769687 07)

Figure 7 (Fdc77d21 Ac52 4c9e B53f 43681e769687 07)
A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The y-axis shows percentage of patients ranging from 0% to 45%. The placebo group (N=97) has approximately 19.6%, while the Levetiracetam group (N=101) has about 44.6%. Asterisk symbol is present above the Levetiracetam bar.*
FDA Label Image

Figure 8 (Fdc77d21 Ac52 4c9e B53f 43681e769687 08)

Figure 8 (Fdc77d21 Ac52 4c9e B53f 43681e769687 08)
Bar chart comparing the percentage of patients between two groups: Placebo (N=51) and Levetiracetam (N=58). The y-axis represents the percentage of patients, with placebo at 19.6% and levetiracetam at 43.1%. The chart highlights a higher percentage in the levetiracetam group.*
FDA Label Image

Figure 9 (Fdc77d21 Ac52 4c9e B53f 43681e769687 09)

Figure 9 (Fdc77d21 Ac52 4c9e B53f 43681e769687 09)
A vertical bar chart comparing the percentage of patients between two groups: Placebo (N=84) with 45.2%, and Levetiracetam (N=79) with 72.2%. The y-axis represents the percentage of patients from 0% to 100%. An asterisk marks the Levetiracetam bar, indicating statistical significance or emphasis.*
FDA Label Image

Label (Lbl636294137)

Label (Lbl636294137)
Label for Levetiracetam 500 mg tablet, film coated, provided by Bryant Ranch Prepack. The label compares this generic tablet to Keppra 500 mg by Lupin Pharmaceuticals, Inc. It includes storage instructions to keep at 20°-25°C and to keep drugs out of reach of children. The NDC highlighted is 63629-4137, and the label indicates a quantity of 90 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.